Article
UK's Syncona writes off 54.5 mln stg after Novartis ends Gyroscope's therapy
Rating:
0.0
Views:
64
Likes:
1
Library:
1
British healthcare investment firm Syncona said on Monday Novartis has stopped the development of experimental eye treatment, GT005, which would result in payments write-off of 54.5 million pounds ($68.23 million) for Gyroscope Holdings Limited.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value